/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Cnbx Pharmaceuticals (CNBX) generated about $0.00 in revenue and -$462,091.00 in net income over the trailing twelve months, growing at roughly 68.4% a year. Figures are from SEC filings; this is analysis, not investment advice.
Cnbx Pharmaceuticals generated about $0.00 in revenue over the trailing twelve months. Revenue has grown at roughly 68.4% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Cnbx Pharmaceuticals reported about -$462,091.00 in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Cnbx Pharmaceuticals's revenue has compounded at roughly 68.4% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside CNBX's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 24 Jun 2026, covering the period ending 31 May 2026, as reported to the SEC. Data last refreshed 25 Jun 2026. How this is calculated.
Fiscal year ends Aug.